{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:07Z","timestamp":1792081507167,"version":"4.4.0"},"reference-count":55,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,8,4]],"date-time":"2014-08-04T00:00:00Z","timestamp":1407110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This randomised, double\u2010blind, 12\u2010week study compared efficacy and tolerability of flexible\u2010dose treatment with vortioxetine (10\u201320\u2009mg\/day) versus agomelatine (25\u201350\u2009mg\/day) in major depressive disorder patients with inadequate response to selective serotonin reuptake inhibitor (SSRI)\/serotonin\u2013noradrenaline reuptake inhibitor (SNRI) monotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients were switched directly from SSRI\/SNRI to vortioxetine or agomelatine. Primary endpoint was change from baseline to week 8 in the Montgomery\u2013\u00c5sberg Depression Rating Scale (MADRS) total score analysed by mixed model for repeated measurements, using a noninferiority test followed by a superiority test. Secondary endpoints included response and remission rates, anxiety symptoms (Hamilton Anxiety Rating Scale), Clinical Global Impression, overall functioning (Sheehan Disability Scale), health\u2010related quality of life (EuroQol 5 Dimensions), productivity (work limitation questionnaire) and family functioning (Depression and Family Functioning Scale).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Primary endpoint noninferiority was established and vortioxetine (<jats:italic>n<\/jats:italic>\u2009=\u2009252) was superior to agomelatine (<jats:italic>n<\/jats:italic>\u2009=\u2009241) by 2.2 MADRS points (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Vortioxetine was also significantly superior in response and remission rates at weeks 8 and 12; MADRS, Hamilton Anxiety Rating Scale, Clinical Global Impression, Sheehan Disability Scale and EuroQol 5 Dimensions scores at week 4 onwards; work limitation questionnaire at week 8 and Depression and Family Functioning Scale at weeks 8 and 12. Fewer patients withdrew because of adverse events with vortioxetine (5.9% vs 9.5%). Adverse events (incidence \u22655%) were nausea, headache, dizziness and somnolence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Vortioxetine was noninferior and significantly superior to agomelatine in major depressive disorder patients with previous inadequate response to a single course of SSRI\/SNRI monotherapy. Vortioxetine was safe and well tolerated. \u00a9 2014 The Authors. <jats:italic>Human Psychopharmacology: Clinical and Experimental<\/jats:italic> published by John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2424","type":"journal-article","created":{"date-parts":[[2014,8,4]],"date-time":"2014-08-04T04:20:58Z","timestamp":1407126058000},"page":"470-482","source":"Crossref","is-referenced-by-count":122,"title":["A randomised, double\u2010blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin\u2013noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine"],"prefix":"10.1002","volume":"29","author":[{"given":"Stuart A.","family":"Montgomery","sequence":"first","affiliation":[{"name":"Imperial College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Z.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lis H.","family":"Poulsen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"H\u00e4ggstr\u00f6m","sequence":"additional","affiliation":[{"name":"Affecta Psychiatric Clinic  Halmstad Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001027"},{"key":"e_1_2_8_3_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association (APA)","year":"2000"},{"key":"e_1_2_8_4_1","unstructured":"American Psychiatric Association (APA).2010.Practice guidelines for the treatment of patients with MDD.3rd edn."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2011.00810.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145705006358"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.11.008"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101459g"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622970701227829"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112441866"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000018"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2009.01.012"},{"key":"e_1_2_8_13_1","unstructured":"CPMP (Committee for Proprietary Medicinal Products).2000.Points to consider on switching between superiority and non\u2010inferiority. July 2000. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003658.pdf. Accessed December 12 2013."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.658910"},{"key":"e_1_2_8_15_1","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833a86aa"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07470"},{"key":"e_1_2_8_19_1","unstructured":"ICH Harmonised Tripartite Guideline E6: guideline for good clinical practice.1996. Available at:http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm073122.pdf. Accessed December 12 2013."},{"key":"e_1_2_8_20_1","unstructured":"JacobsenPL MahableshwarkarAR SerenkoM ChanS TrivediM.2013.A randomized double\u2010blind placebo\u2010controlled study of the efficacy and safety of vortioxetine 10\u2009mg and 20\u2009mg in adults with major depressive disorder. Poster NR9\u201006 presented at the 166th Annual Meeting of the APA San Francisco CA USA. Abstract available athttp:\/\/www.psychiatry.org\/learn\/library\u2010\u2010archives"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.07.001"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05347blu"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283542457"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318172b48c"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","unstructured":"KirschI MooreTJ ScoboriaA NichollsSS.2002.The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention Treatment 2002;5 art. 23. Available online at:http:\/\/psycnet.apa.org\/?&fa=main.doiLanding&doi=10.1037\/1522\u20103736.5.1.523a","DOI":"10.1037\/\/1522-3736.5.1.523a"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.120196"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(97)83296-8"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1112"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3282f424c2"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200101000-00009"},{"key":"e_1_2_8_31_1","unstructured":"MahableshwarkarA JacobsenPL SMl ChenY TrivediM.2013a.A duloxetine\u2010referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult patients with MDD. Poster NR9\u201001 presented at the 166th Annual Meeting of the APA San Francisco CA USA. Abstract available athttp:\/\/www.psychiatry.org\/learn\/library\u2010\u2010archives"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.761600"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.06.003"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3280c56b13"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32832a8eb2"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000137184.64610.c8"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2013.01.019"},{"key":"e_1_2_8_39_1","unstructured":"NICE.2009.(National Institute for Health and Clinical Excellence). Clinical Guideline 90 (CG90)\u2014the treatment and management of depression in adults. Available at:http:\/\/guidance.nice.org.uk\/CG90. Accessed December 12 2013."},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.7.1069"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1988.tb06402.x"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(93)90104-R"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3282f2b4d6"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199606003-00015"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(98)00004-2"},{"key":"e_1_2_8_46_1","unstructured":"SPC (Summary of Product Characteristics) for agomelatine (Valdoxan).2009. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000915\/WC500046227.pdf. Accessed 12 December 2013."},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.01.002"},{"key":"e_1_2_8_48_1","volume-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor D","year":"2012"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1888"},{"issue":"13","key":"e_1_2_8_50_1","first-page":"23","article-title":"When at first you don't succeed: sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase ME","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.3.233"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"issue":"1","key":"e_1_2_8_53_1","first-page":"47","article-title":"In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets","volume":"16","author":"Westrich L","year":"2012","journal-title":"Int J Psychiatry Clin Pract"},{"key":"e_1_2_8_54_1","doi-asserted-by":"crossref","unstructured":"World Medical Association (WMA).2008. [Homepage on the Internet]. Declaration of Helsinki: Ethical principles for medical research involving human subjects.","DOI":"10.1515\/9783110208856.233"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696990903093537"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-9-10"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2424","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hup.2424","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T15:59:16Z","timestamp":1696521556000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,4]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1002\/hup.2424"],"URL":"https:\/\/doi.org\/10.1002\/hup.2424","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,4]]}}}